共查询到18条相似文献,搜索用时 156 毫秒
1.
目的 建立131I标记17-丙烯胺基-17.去甲氧基格尔德霉素(17-AAG)的方法,并观察其在动物体内的生物分布.方法 采用过氧化氢法对17-AAG进行131I标记.测定131I.17.AAG注射后0.5,1,4,8和24 h在ICR健康小鼠体内的生物分布,通过显像动态观察131I-17-AAG在兔Vχ2肝癌模型中的分布.结果 建立了131I过氧化氢法标记17-AAG的最佳条件,131I-17-AAG标记率达85.65%,纯化后其乙酸乙酯相、生理盐水水溶液和4℃下放置5 d的生理盐水水溶液的放化纯分别为(96.51±0.80)%,(95.57±0.09)%和(90.96±1.29)%.尾静脉注射131I-17-AAG,健康ICR小鼠胆囊的摄取(每克组织百分注射剂量率,%ID/g)在0.5 h达到峰值(3.0963±1.3394)%ID/g,胃和小肠的摄取均在4 h达到高峰,24 h时肠道放射性明显减少,肝、肾摄取较少.瘤体给药后于2 h和4,6,14 d进行显像,可见131I-17-AAG在兔肿瘤中持续浓聚,肿瘤/非肿瘤组织放射性(T/NT)比值分别为10.36,3.62,4.32和3.50,其他脏器未见显影.结论 成功建立了131I-17-AAG标记方法,标记物保留了17-AAG生物学活性,体外稳定性好.兔肝肿瘤间质给药提示131I-17-AAG对肿瘤具有理想靶向性作用. 相似文献
2.
3.
4.
目的 探讨^131I-17-丙烯胺基-17-去甲氧基格尔德霉素(17-AAG)对人乳腺癌细胞生长的影响及其相关机制。方法 采用过氧化氢标记法制备^131I-17-AAG。细胞杀伤实验分为5组:二甲基亚砜(DMSO)对照(A)组,Na^131I370kBq(B)组,17-AAG2.5mg/L(C)组,^131I-17-AAG370kBq(D)组,^131I-17-AAG370kBq+17-AAG2.5mg/L(E)组。用四甲基偶氮唑蓝(MTT)法检测各种药物对人乳腺癌细胞MCF-7的生长抑制作用,流式细胞术分析细胞凋亡及细胞周期变化,RT—PCR检测药物处理前后MCF-7细胞中Akt2基因的mRNA表达情况。结果 ^131I-17-AAG的标记率为83%,放化纯为96.6%,比活度为1.48×10^5MBq/μmol。各组药物对细胞的杀伤呈时间效应,随着时间的延长,细胞的抑制率都呈明显上升趋势,尤以E组趋势明显。A~E组药物作用48h后,通过亚G1峰检测MCF-7细胞凋亡率分别为(1.54±0.13)%,(5.72±1.05)%,(12.97±1.44)%,(20.65±1.36)%,(35.39±4.15)%,各组细胞凋亡率差异有统计学意义(P均〈0.05)。C组,D组及E组Akt2基因的mRNA表达均比A组降低,其中E组降低尤为明显。结论 ^131I-17AAG能够抑制MCF-7细胞的生长并促进其凋亡,且能有效抑制Akt2基因的mRNA表达,和17-AAG联合应用能够增强肿瘤细胞对放疗的敏感性。 相似文献
5.
6.
7.
8.
9.
10.
11.
Tu Wenyong Liu Lu Chen Daozhen Yin Weidong Huang Ying 《Annals of nuclear medicine》2009,23(2):113-122
Objective To observe the antitumor effect of 131I-17-allylamino-17-demethoxygeldanamycin (131I-17-AAG) in vitro/in vivo and explore its antitumor mechanism with a view to its potential therapeutic application.
Methods
131I-17-AAG was prepared by the reaction of 17-AAG with Na [131I] in the presence of hydrogen peroxide. The effects of 13117-AAG on cell growth inhibition and cell cycle distribution in vitro were studied in BEL-7402 cells lines. Following BEL-7402
tumor implantation by subcutaneous xenografts into nude mice, the reagents were injected through the tail vein, and the tumor
volume was measured and analyzed. At the end of the experiment, tumor specimens were processed for histopathological analysis.
Terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) was used to investigate apoptosis. The expression
change of Akt2 was tested by Western-blot analysis.
Results Methyl-thiazolyl-tetrazolium assay showed inhibition rates of 27.7 ± 5.3%, 57.3 ± 4.3%, and 63.7 ± 3.1%, in Na131I group, 17-AAG group, and 131I-17-AAG group, respectively. The inhibition rate in the 131I-17-AAG group differed significantly between Na131I group and 17-AAG group (F = 229.49, P < 0.001). Following 48 h of treatment with the drug in each group, flow cytometry analysis indicated that detected sub-G
peaks (black) were 1.54 ± 0.13%, 5.72 ± 1.05%, 12.97 ± 1.44%, and 20.65 ± 1.36%, in dimethyl sulfoxide (DMSO) group, Na131I group, 17-AAG group, and 131I-17-AAG group, respectively. Following infusion for 32 days, the tumor volumes in the 131I-17-AAG group were significantly smaller than those in the DMSO group (F = 24.18, P < 0.001) or the 131I group (F = 20.68, P < 0.001). Histopathological and TUNEL analyses showed that 131I-17-AAG inhibited the proliferation of tumor cells and induced apoptosis. The expression of Akt2 in 131I-17-AAG was significantly lower than that in the DMSO group or 131I group.
Conclusions
131I-17-AAG can effectively inhibit the growth of BEL-7402 tumor cells in vitro and in vivo. 131I-17-AAG is a promising agent for the treatment of BEL-7402 cell tumor. 相似文献
12.
17-AAG对转染NIS基因的未分化甲状腺癌摄碘动力学的影响 总被引:1,自引:0,他引:1
目的 探讨17-丙烯胺基-17-去甲氧基格尔德霉素(17-AAG)对已转染NIS基因的未分化甲状腺癌(ATC)细胞摄碘动力学的影响.方法 采用脂质体转染法,将携带NIS基因的重组质粒pcDNA3.1-NIS转染入ATC细胞株FRO细胞中,G418抗性筛选获得稳定表达细胞系NIS-FRO.在NIS-FRO细胞的培养基中引入125I,进行125I内流及外流的系列实验,绘制时间-放射性曲线.进一步分析经1μmol/L的17-AAG作用24 h后NIS-FRO细胞125I内流及外流的变化,并与未经转染的细胞进行对比,2组间各个时间点的放射性计数采用两样本t检验进行统计学分析.结果 NIS-FRO细胞的摄125I能力明显提高,约为FRO细胞的10.68倍(t=45.329,P<0.001),但去除孵育环境中的125I后30 min,细胞内的125I滞留率仅为初始的10.5%.1μmol/L的17-AAG作用于NIS-FRO细胞后24h,细胞摄125I能力进一步提高,在含125I的培养基中孵育20~60 min,其放射性计数为31771.8~54815.5 min-1,摄125I能力较对照组( 24020.3~41293.8)提高了24.8%~ 35.5%(t值依次为3.096、4.275、3.055、4.292和5.496,P均<0.05);撤掉孵育环境中的131I后5~30 min,细胞内的125I滞留率为32.7% ~85.2%,较对照组(10.5%~56.8%)明显增加(t值依次为22.801、13.096、19.631、38.205、43.519和29.322,P均<0.01),125I的外流减少,30 min后17-AAG作用组的细胞内125I滞留率为32.7%,为对照组的3.1倍.结论 把NIS转染入ATC细胞后获得的稳定表达细胞株在经一定浓度的17-AAG作用后,可进一步提高肿瘤细胞的摄碘率,并可明显延迟碘的外流,提高细胞内碘的滞留率. 相似文献
13.
目的 研制直径100~200 nm的125I-脱氧尿嘧啶核苷-壳聚糖载药纳米微粒( 125I-UdR-CS-DLN),并进一步分析其药物缓释性能和肿瘤靶向性。方法 采用离子交联法制备CS纳米微粒,以单因素分析和正交试验优化制备条件和工艺;用动态透析法分析其释放特性;激光共聚焦显微镜观察其肿瘤靶向性。结果 按照CS浓度1 g/L,搅拌速度600 r/min,TPP浓度2 g/L,相对分子质量为3×103的条件下得到平均粒径(70.39±5.12) nm的纳米微粒(PDI为0.16±0.012)。透射电镜观察其外观为规整的球形,大小均匀,分散度较好。在投药量为2.96 MBq/ml、pH值为5的条件下, 125I-UdR-CS-DLN的载药量1253.55 MBq/g,包封率42.35%,具有明显的缓释作用。激光共聚焦显微镜观察结果证明肿瘤细胞在2 h内摄入的纳米粒子明显多于正常细胞。结论 成功制备了直径为(127.81±15.25) nm (PDI 为0.240±0.035)的 125I-UdR-CS-DLN,确定了最佳工艺条件。所制备的纳米粒子具有典型的长效缓释制剂特性,并具有肿瘤细胞被动靶向性,为 125I-UdR应用于肿瘤内照射治疗提供了更有效的途径。 相似文献
14.
Gamma camera dual imaging with a somatostatin receptor and thymidine kinase after gene transfer with a bicistronic adenovirus in mice 总被引:3,自引:0,他引:3
Zinn KR Chaudhuri TR Krasnykh VN Buchsbaum DJ Belousova N Grizzle WE Curiel DT Rogers BE 《Radiology》2002,223(2):417-425
PURPOSE: To compare two systems for assessing gene transfer to cancer cells and xenograft tumors with noninvasive gamma camera imaging. MATERIALS AND METHODS: A replication-incompetent adenovirus encoding the human type 2 somatostatin receptor (hSSTr2) and the herpes simplex virus thymidine kinase (TK) enzyme (Ad-hSSTr2-TK) was constructed. A-427 human lung cancer cells were infected in vitro and mixed with uninfected cells at different ratios. A-427 tumors in nude mice (n = 23) were injected with 1 x 10(6) to 5 x 10(8) plaque-forming units (pfu) of Ad-hSSTr2-TK. The expressed hSSTr2 and TK proteins were imaged owing to internally bound, or trapped, technetium 99m ((99m)Tc)-labeled hSSTr2-binding peptide (P2045) and radioiodinated 2'-deoxy-2'-fluoro-beta-D-arabinofuranosyl-5-iodouracil (FIAU), respectively. Iodine 125 ((125)I)-labeled FIAU was used in vitro and iodine 131 ((131)I)-labeled FIAU, in vivo. The (99m)Tc-labeled P2045 and (125)I- or (131)I-labeled FIAU were imaged simultaneously with different window settings with an Anger gamma camera. Treatment effects were tested with analysis of variance. RESULTS: Infected cells in culture trapped (125)I-labeled FIAU and (99m)Tc-labeled P2045; uptake correlated with the percentage of Ad-hSSTr2-TK-positive cells. For 100% of infected cells, 24% +/- 0.4 (mean +/- SD) of the added (99m)Tc-labeled P2045 was trapped, which is significantly lower (P <.05) than the 40% +/- 2 of (125)I-labeled FIAU that was trapped. For the highest Ad-hSSTr2-TK tumor dose (5 x 10(8) pfu), the uptake of (99m)Tc-labeled P2045 was 11.1% +/- 2.9 of injected dose per gram of tumor (thereafter, dose per gram), significantly higher (P <.05) than the uptake of (131)I-labeled FIAU at 1.6% +/- 0.4 dose per gram. (99m)Tc-labeled P2045 imaging consistently depicted hSSTr2 gene transfer in tumors at all adenovirus doses. Tumor uptake of (99m)Tc-labeled P2045 positively correlated with Ad-hSSTr2-TK dose; (131)I-labeled FIAU tumor uptake did not correlate with vector dose. CONCLUSION: The hSSTr2 and TK proteins were simultaneously imaged following dual gene transfer with an adenovirus vector. 相似文献
15.
目的 研究131I-antiEGFR-BSA-PCL对LS180细胞结肠癌裸鼠移植瘤内照射的治疗效果。方法 构建抗表皮生长因子受体(EGFR)标记的纳米脂质体及EGFR靶向性。通过荧光共聚焦显微镜、细胞摄碘实验观察纳米载体的靶向性及LS180细胞对其摄取情况。将裸鼠40只按随机数字表法分为4组,通过瘤体内注射的方式向移植瘤内分别注射74 MBq (740 MBq/ml) 131I-antiEGFR-BSA-PCL、131I-BSA-PCL、131I及相同体积的生理盐水。通过研究裸鼠体重、肿瘤体积、SPECT显像及组织病理学方法,观察纳米脂质体的抑瘤效果。结果 共聚焦实验显示,与BSA-PCL组相比,antiEGFR-BSA-PCL组细胞内绿色荧光较明显,其介导的胞吞效应显著。摄碘率实验中,LS180细胞对131I-antiEGFR-BSA-PCL的摄取率明显高于131I-BSA-PCL(t=2.77~5.40,P<0.01)。131I-antiEGFR-BSA-PCL组与131I-BSA-PCL组裸鼠肿瘤增殖均较慢,二者差异无统计学意义(P>0.05)。给药后72 h,131I-antiEGFR-BSA-PCL与131I-BSA-PCL的肿瘤摄取率分别为(21.61±1.01)和(20.58±0.65)% ID/g,均明显高于131I组(t=9.36、8.69,P<0.01)。SPECT显像显示纳米脂质体主要特异性积聚在肿瘤区。结论 131I-antiEGFR-BSA-PCL对LS180结肠癌裸鼠移植瘤有明显的抑制作用。 相似文献
16.
17.
目的 观察131I标记17-丙烯胺基-17-去甲氧基格尔德霉素(17-KAG)对荷H460人非小细胞肺癌裸鼠移植瘤的抑癌效应.方法 过氧化氢法制备131I-17AAG.建立荷H460人非小细胞肺癌BALB/c裸鼠模型,28只荷瘤裸鼠按随机数字表法分为7组(n=4),瘤内和尾静脉注药各3组,剂量依次为5.5 MBq×2(间隔8 d)、11.0 MSq和5.5 MBq及空白对照组.另设Na131I瘤内给药对照组.8组分别于注药后2,6,24 h及2,3,7,10,16 d各取2只鼠行γ显像.观察肿瘤生长情况,16 d后处死全部小鼠,计算抑瘤率,并做光学显微镜、电镜及免疫组织化学检测.计量数据以x±s表示,采用SPSS 13.0软件进行统计分析.结果 SPECT显像证实131I-17-AAG靶向定位好,能较长时间聚集在瘤体内;各治疗组存在不同程度抑瘤效应,以瘤内间隔给药(5.5 MBq×2)组疗效最好,抑瘤率高达(86.77±4.57)%,尾静脉给药5.5 MBq×2组和11.0 MBq组间差异无统计学意义(q=1.67,P>0.05),余各组间抑瘤率差异均有统计学意义(q=3.16~24.34,P均<0.05);形态学显示抑瘤效应越好,瘤组织破坏越明显;免疫组织化学显示瘤内及尾静脉注药组热休克蛋白90(HSP90)a阳性率[分别为(26.01±3.71)%、(61.57±5.98)%]均较空白对照组[(84.13±5.71)%]下降(t值分别为20.91和6.68,P均<0.05).结论 131I-17-AAG能有效抑制裸鼠非小细胞肺癌的生长,以瘤内注药及间隔给药抑癌效应最佳. 相似文献
18.
Sang Mi Lee Jeong Won Lee Shin Young Kim Seon Wook Han Won Kyoung Bae 《Annals of nuclear medicine》2013,27(8):700-709